NO20060128L - Krystallinske tumornekrosesfaktor reseptor 2-polypeptider - Google Patents
Krystallinske tumornekrosesfaktor reseptor 2-polypeptiderInfo
- Publication number
- NO20060128L NO20060128L NO20060128A NO20060128A NO20060128L NO 20060128 L NO20060128 L NO 20060128L NO 20060128 A NO20060128 A NO 20060128A NO 20060128 A NO20060128 A NO 20060128A NO 20060128 L NO20060128 L NO 20060128L
- Authority
- NO
- Norway
- Prior art keywords
- polypeptides
- crystalline
- necrosis factor
- tumor necrosis
- factor receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Det beskrives krystallinske polypeptider og fremgangsmåter for fremstilling av disse; farmasøytiske blandinger som omfatter krystallinske polypeptider; og terapeutisk anvendelser av slike polypeptider og blandinger.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49182703P | 2003-08-01 | 2003-08-01 | |
PCT/US2004/024738 WO2005012353A1 (en) | 2003-08-01 | 2004-07-29 | Crystalline tumor necrosis factor receptor 2 polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060128L true NO20060128L (no) | 2006-04-06 |
Family
ID=34115556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060128A NO20060128L (no) | 2003-08-01 | 2006-01-09 | Krystallinske tumornekrosesfaktor reseptor 2-polypeptider |
Country Status (19)
Country | Link |
---|---|
US (1) | US7276477B2 (no) |
EP (1) | EP1654281A1 (no) |
JP (1) | JP2007521315A (no) |
KR (1) | KR20070008501A (no) |
CN (1) | CN100509847C (no) |
AU (1) | AU2004262014B2 (no) |
BR (1) | BRPI0413197A (no) |
CA (1) | CA2533796A1 (no) |
CR (1) | CR8224A (no) |
EC (1) | ECSP066299A (no) |
HK (1) | HK1093749A1 (no) |
IL (1) | IL173413A0 (no) |
NO (1) | NO20060128L (no) |
NZ (1) | NZ545221A (no) |
RU (1) | RU2006101216A (no) |
SG (1) | SG145712A1 (no) |
TW (1) | TWI291468B (no) |
WO (1) | WO2005012353A1 (no) |
ZA (1) | ZA200600909B (no) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005105133A2 (en) * | 2004-04-23 | 2005-11-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US20060046960A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
JP2008528006A (ja) * | 2005-01-28 | 2008-07-31 | アポロ ライフ サイエンシズ リミテッド | 分子およびそのキメラ分子 |
CN1954882A (zh) * | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
MX2008006089A (es) * | 2005-11-10 | 2009-05-28 | Santaris Pharma As | Oligomeros de conmutacion de empalme para los receptores de la super-familia de tnf y su uso en el tratamiento de enfermedades. |
US20090215744A1 (en) * | 2005-11-18 | 2009-08-27 | Astrazeneca Ab | Solid Formulations |
US20090069292A1 (en) * | 2005-11-18 | 2009-03-12 | Astrazeneca Ab | Liquid Formulations |
US8389510B2 (en) * | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
CN101360502B (zh) * | 2005-11-18 | 2012-03-14 | 阿斯利康公司 | 结晶形式 |
EP1951694A4 (en) * | 2005-11-18 | 2010-09-22 | Astrazeneca Ab | FORMS OF SALTS |
WO2007100937A2 (en) * | 2006-01-19 | 2007-09-07 | The Regents Of The University Of Michigan | System and method for spectroscopic photoacoustic tomography |
US9012605B2 (en) | 2006-01-23 | 2015-04-21 | Amgen Inc. | Crystalline polypeptides |
WO2008063639A2 (en) | 2006-11-21 | 2008-05-29 | Massachusetts Eye And Ear Infirmary | Compositions and methods for preserving cells of the eye |
US20080123083A1 (en) * | 2006-11-29 | 2008-05-29 | The Regents Of The University Of Michigan | System and Method for Photoacoustic Guided Diffuse Optical Imaging |
WO2009018429A2 (en) * | 2007-07-31 | 2009-02-05 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healt Of Human Services, National Institutes Of Healt | TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2 |
EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
BRPI0908361A2 (pt) * | 2008-02-07 | 2015-04-07 | Amgen Inc | Seringas previamente cheias contendo composição e métodos de preparação das mesmas e de estabilização de agente de ligação específico em composição. |
CN101591388A (zh) * | 2008-05-30 | 2009-12-02 | 上海复旦张江生物医药股份有限公司 | 一种可溶性tnf受体突变体 |
CA2769011C (en) | 2009-07-28 | 2017-06-06 | Xcellerex, Inc. | Vaccine stabilizer |
EP2461818B1 (en) | 2009-08-03 | 2018-10-17 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
ES2796530T3 (es) | 2009-10-26 | 2020-11-27 | Prometheus Biosciences Inc | Ensayos para la detección de fármacos anti-TNF y autoanticuerpos |
JP2013512674A (ja) * | 2009-12-02 | 2013-04-18 | アクセルロン ファーマ, インコーポレイテッド | Fc融合タンパク質の血清半減期を増加させるための組成物および方法 |
US8759284B2 (en) | 2009-12-24 | 2014-06-24 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
CN102946858B (zh) * | 2010-05-10 | 2015-09-30 | 英塔斯制药有限公司 | 含有免疫球蛋白Fc的多肽的液体制剂 |
AU2011317149B2 (en) | 2010-10-18 | 2015-05-07 | Société des Produits Nestlé S.A. | Methods for determining anti-drug antibody isotypes |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8846040B2 (en) * | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
WO2012115904A2 (en) * | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Production of n- and o-sialylated tnfrii-fc fusion protein in yeast |
US9453067B2 (en) | 2011-04-20 | 2016-09-27 | Sandoz Ag | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
EP2718328A4 (en) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM |
MX358137B (es) * | 2011-07-01 | 2018-08-06 | Biogen Idec Inc | Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso. |
EP2729807B1 (en) | 2011-07-06 | 2016-08-17 | Nestec S.A. | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
WO2013059410A1 (en) | 2011-10-18 | 2013-04-25 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with xylitol |
EA029193B1 (ru) * | 2012-07-09 | 2018-02-28 | Кохерус Байосайенсис, Инк. | Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона |
EP2895188B1 (en) | 2012-09-11 | 2017-11-15 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
EP2916656B1 (en) * | 2012-11-09 | 2017-10-25 | Cornell University | Small molecule inhibitors of malt1 |
US9649383B2 (en) | 2012-11-19 | 2017-05-16 | Merck Sharp & Dohme Corp. | Liquid formulations for TNFR:Fc fusion proteins |
KR101419884B1 (ko) | 2012-11-27 | 2014-07-16 | (주)알테오젠 | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 |
CA2930227C (en) | 2013-11-29 | 2021-09-28 | Ares Trading S.A. | A liquid formulation of a fusion protein comprising tnfr and fc region |
ES2733298T3 (es) | 2014-07-18 | 2019-11-28 | Sandoz Ag | Cuantificación de TNFR2:Fc plegado erróneamente |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US10080877B2 (en) | 2014-07-25 | 2018-09-25 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a drug cartridge |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
EP3017825A1 (en) * | 2014-11-06 | 2016-05-11 | Ludwig-Maximilians-Universität München | An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same |
WO2016083331A1 (en) * | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
EP3536705A1 (en) | 2014-12-05 | 2019-09-11 | Société des Produits Nestlé S.A. | Isolated soluble alpha-4 integrin, beta-7 integrin and alpha-4/beta-7 heterodimer integrin |
US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
EP3236990B1 (en) | 2014-12-22 | 2020-09-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
JP6682734B2 (ja) * | 2015-01-27 | 2020-04-15 | ビージーアイ シェンチェン | 生体試料を保存するための安定化剤 |
WO2016140922A1 (en) | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
USD802755S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
CA3039136A1 (en) | 2016-09-02 | 2018-03-08 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
US11692027B2 (en) | 2016-09-28 | 2023-07-04 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
EP3533441A4 (en) | 2016-10-28 | 2019-12-04 | Celltrion Inc. | STABLE PHARMACEUTICAL FORMULATION |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
WO2020003139A2 (en) * | 2018-06-26 | 2020-01-02 | Lupin Limited | Stable lyophilized dosage form of protein |
KR20210027409A (ko) * | 2018-07-03 | 2021-03-10 | 페넥 파마슈티컬스, 인크. | 무수 싸이오황산나트륨 및 이의 제형 |
CN111408343B (zh) * | 2019-01-08 | 2022-01-28 | 湖南农业大学 | 三维立体生物炭的制备方法及其在重金属吸附中的应用 |
CN110433172B (zh) * | 2019-07-10 | 2022-04-08 | 郴州市第一人民医院 | 一种具有治疗非小细胞肺癌功效的药物及其用途 |
AU2021410709A1 (en) | 2020-12-22 | 2023-05-25 | Amgen Inc. | Cell culture method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
EP2325205A3 (en) * | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
-
2004
- 2004-07-29 RU RU2006101216/04A patent/RU2006101216A/ru unknown
- 2004-07-29 US US10/901,735 patent/US7276477B2/en active Active
- 2004-07-29 EP EP04779710A patent/EP1654281A1/en not_active Ceased
- 2004-07-29 SG SG200805780-4A patent/SG145712A1/en unknown
- 2004-07-29 AU AU2004262014A patent/AU2004262014B2/en not_active Ceased
- 2004-07-29 WO PCT/US2004/024738 patent/WO2005012353A1/en active Application Filing
- 2004-07-29 CN CNB2004800214984A patent/CN100509847C/zh not_active Expired - Fee Related
- 2004-07-29 NZ NZ545221A patent/NZ545221A/en unknown
- 2004-07-29 KR KR1020067001733A patent/KR20070008501A/ko not_active Application Discontinuation
- 2004-07-29 BR BRPI0413197-5A patent/BRPI0413197A/pt not_active Application Discontinuation
- 2004-07-29 CA CA002533796A patent/CA2533796A1/en not_active Abandoned
- 2004-07-29 JP JP2006522109A patent/JP2007521315A/ja active Pending
- 2004-08-02 TW TW093123111A patent/TWI291468B/zh not_active IP Right Cessation
-
2006
- 2006-01-09 NO NO20060128A patent/NO20060128L/no not_active Application Discontinuation
- 2006-01-20 EC EC2006006299A patent/ECSP066299A/es unknown
- 2006-01-29 IL IL173413A patent/IL173413A0/en unknown
- 2006-01-31 ZA ZA200600909A patent/ZA200600909B/en unknown
- 2006-02-01 CR CR8224A patent/CR8224A/es not_active Application Discontinuation
-
2007
- 2007-01-19 HK HK07100718.4A patent/HK1093749A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US7276477B2 (en) | 2007-10-02 |
US20050032183A1 (en) | 2005-02-10 |
WO2005012353A1 (en) | 2005-02-10 |
KR20070008501A (ko) | 2007-01-17 |
RU2006101216A (ru) | 2007-07-20 |
IL173413A0 (en) | 2006-06-11 |
ZA200600909B (en) | 2007-05-30 |
NZ545221A (en) | 2009-09-25 |
CR8224A (es) | 2006-07-18 |
SG145712A1 (en) | 2008-09-29 |
CN100509847C (zh) | 2009-07-08 |
CN1829739A (zh) | 2006-09-06 |
TWI291468B (en) | 2007-12-21 |
AU2004262014A1 (en) | 2005-02-10 |
CA2533796A1 (en) | 2005-02-10 |
JP2007521315A (ja) | 2007-08-02 |
HK1093749A1 (en) | 2007-03-09 |
AU2004262014B2 (en) | 2010-06-17 |
TW200510453A (en) | 2005-03-16 |
EP1654281A1 (en) | 2006-05-10 |
ECSP066299A (es) | 2006-07-28 |
BRPI0413197A (pt) | 2006-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060128L (no) | Krystallinske tumornekrosesfaktor reseptor 2-polypeptider | |
NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
NO20052524L (no) | Aminerte isofiavonoidderivater og anvendelse derav | |
IS7543A (is) | Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær | |
DK1490062T3 (da) | Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf | |
IS7859A (is) | Indasól efnasambönd og lyfjasamsetningar til að hindra prótín kínasa og aðferðir við notkun þeirra | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
PL372809A1 (en) | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | |
NO20052888L (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
NO20051966L (no) | Nye pyrimidinamidderivater og anvendelse derav | |
IS2376B (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
NO20093060L (no) | Spirosykliske sykloheksanderivater | |
DK1523488T3 (da) | Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse | |
DK1784426T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
NO20085373L (no) | P38 inhibitorer, deres fremstilling og anvendelse | |
SE0301700D0 (sv) | Novel compounds | |
NO20042155L (no) | N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling | |
NO20085338L (no) | Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav | |
NO20002787L (no) | Nye forbindelser | |
NO20090348L (no) | Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme | |
DK1458713T3 (da) | Indolinonderivater anvendelige som proteinkinaseinhibitorer | |
NO20055838D0 (no) | Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav | |
IL161582A0 (en) | Use of oxindole hydrazide derivatives for the preparation of pharmaceutical compositions, certain such new derivatives and their preparation | |
NO20062878L (no) | Isoflavonoidpromedikamenter, terapeutiske sammensetninger derav og terapeutiske fremgangsmater som innbefatter de samme | |
NO20030849L (no) | Nytt salt av perindopril og farmasöytiske sammensetninger inneholdende det |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |